Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Intron A interferon alpha-2b data

Schering-Plough reported results of a Phase III trial of Intron A in 280 high-risk malignant melanoma patients. The

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE